Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Acocella

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Pharmacological Research Communications|March 1, 1978
Multicompartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl-rifampicin in subjects treated for one weekG Acocella, R Mattiussi, G Segre
Minerva Stomatologica|March 12, 2002
[Nodular fasciitis in the zygomatic area. Case report and review of the literature]G Acocella, N Nardi, A Acocella
Lancet (London, England)|July 1, 1978
Rifampicin and the liverG Acocella, A Luvará, M Guaglianone
Minerva Stomatologica|July 23, 2003
[Sequelae of zygomatic-orbito-maxillary fractures. Report of 70 cases and review of literature]P Nardi, A Acocella, G Acocella
Tijdschrift Voor Gastro-Enterologie|January 1, 1973
Serum concentrations and biliary excretion of bilirubin during short-term treatment with rifampicinG Acocella, R Mattiussi, L T Tenconi
Bollettino Chimico Farmaceutico|February 1, 1972
[Multicompartimental model for the study of drugs with high biliary excretion, used in the study of the kinetics of rifampicin in man]G Acocella, V Pagani, F B Nicolis
Lancet (London, England)|April 2, 1977
Can rifampicin use be safely extended? Evidence for non-emergence of resistant strains of Mycobacterium tuberculosisG Acocella, J M Hamilton-Miller, W Brumfitt
Thorax|October 1, 1980
Evidence that rifampicin can be used safely for non-tuberculous diseasesG Acocella, W Brumfitt, J M Hamilton-Miller
The American Review of Respiratory Disease|October 1, 1988
Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose studyG Acocella, A Nonis, G Gialdroni-Grassi, et al.
The American Review of Respiratory Disease|September 1, 1985
Pharmacokinetic studies on antituberculosis regimens in humans. I. Absorption and metabolism of the compounds used in the initial intensive phase of the short-course regimens: single administration studyG Acocella, R Conti, M Luisetti, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Pharmacological Research Communications|March 1, 1978
Multicompartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl-rifampicin in subjects treated for one weekG Acocella, R Mattiussi, G Segre
Minerva Stomatologica|March 12, 2002
[Nodular fasciitis in the zygomatic area. Case report and review of the literature]G Acocella, N Nardi, A Acocella
Lancet (London, England)|July 1, 1978
Rifampicin and the liverG Acocella, A Luvará, M Guaglianone
Minerva Stomatologica|July 23, 2003
[Sequelae of zygomatic-orbito-maxillary fractures. Report of 70 cases and review of literature]P Nardi, A Acocella, G Acocella
Tijdschrift Voor Gastro-Enterologie|January 1, 1973
Serum concentrations and biliary excretion of bilirubin during short-term treatment with rifampicinG Acocella, R Mattiussi, L T Tenconi
Bollettino Chimico Farmaceutico|February 1, 1972
[Multicompartimental model for the study of drugs with high biliary excretion, used in the study of the kinetics of rifampicin in man]G Acocella, V Pagani, F B Nicolis
Lancet (London, England)|April 2, 1977
Can rifampicin use be safely extended? Evidence for non-emergence of resistant strains of Mycobacterium tuberculosisG Acocella, J M Hamilton-Miller, W Brumfitt
Thorax|October 1, 1980
Evidence that rifampicin can be used safely for non-tuberculous diseasesG Acocella, W Brumfitt, J M Hamilton-Miller
The American Review of Respiratory Disease|October 1, 1988
Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose studyG Acocella, A Nonis, G Gialdroni-Grassi, et al.
The American Review of Respiratory Disease|September 1, 1985
Pharmacokinetic studies on antituberculosis regimens in humans. I. Absorption and metabolism of the compounds used in the initial intensive phase of the short-course regimens: single administration studyG Acocella, R Conti, M Luisetti, et al.
Pageof 5